WO2011149025A1

WO2011149025A1 - Body temperature rising agent for oral administration

Info

Publication number: WO2011149025A1
Application number: PCT/JP2011/062120
Authority: WO
Inventors: 義弘河智; 文也有本; 光広松村; 知憲灘本
Original assignee: 株式会社上野忠
Priority date: 2010-05-28
Filing date: 2011-05-26
Publication date: 2011-12-01
Also published as: JPWO2011149025A1

Abstract

A body temperature rising agent for oral administration, which comprises a plant belonging to the genus Artemisia or a product of any treatment of the plant as an active ingredient.

Description

Oral body temperature increasing agent

The present invention relates to an oral body temperature raising agent, a metabolism promoting agent and an immune function enhancing agent.

As a means of warming the body, a method of promoting blood circulation by using a limb massage or a commercially available hot compress, a method of ingesting alcoholic beverages, a method of taking heat into the body by ingesting warm food, etc., and body temperature It is known to take pepper, ginger, etc. that are said to increase However, in these methods, blood circulation is temporarily promoted immediately after use, and a warming feeling of the body is obtained, but the effect is not sustained. For this reason, the body temperature raising agent which brings a sufficient body warming feeling was calculated | required.

In general, various causes are considered for coldness, but the main causes are decreased blood flow, decreased body heat production such as autonomic balance, disease, hormonal effects, constitution, life Customs are listed. If the body temperature is lowered due to coldness, etc., there are problems such as a decrease in metabolism, back pain, and stiff shoulders. Moreover, when the body cools, the temperature in the body decreases, for example, the intestinal temperature decreases. It is known that a decrease in intestinal temperature causes constipation because it decreases the peristaltic movement of the intestine, and further adverse effects on health due to an increase in bad bacteria in the intestine. Furthermore, a decrease in body temperature reduces immune function. For this reason, a means for raising body temperature and improving the coldness is desired.

Artemisia plants such as Artemisia Artemisia (Artemisia princeps Pampan.) Are perennials of the Asteraceae family that grow naturally in the mountains. Artemisia plants have been widely used for food, and are also used for traditional Chinese medicine. Artemisia plants are sometimes used in folk remedies, and are said to be effective for high blood pressure, cough, kidney disease, neuralgia, rheumatism, low back pain, headache, fever, cancer, leukemia and the like. Patent Document 1 discloses that a mugwort extract composition has a blood glucose rise inhibitory action.
However, there is no scientifically verified example of the effect of increasing body temperature when orally taking a Artemisia plant, and the actual effect is unknown.

JP 2004-67600 A

The present invention can increase body temperature continuously, has low side effects and has high safety, and an oral body temperature increasing agent, and promotes metabolism and enhances immune function by increasing body temperature. It aims at providing the means to do. The present invention also provides a means for preventing or ameliorating coldness.

As a result of diligent research in view of the above situation, the present inventors have found that, when orally ingested pulverized leaves of Artemisia plants, body temperature rises, especially that the temperature of the trunk, such as the abdomen, rises significantly. It was. There has been no report demonstrating that the body temperature rises when ingesting a Artemisia plant, and it was a surprising finding that Artemisia plants have such an excellent body temperature raising action. The present inventors have also found that the body temperature increasing action of Artemisia plants is persistent. When body temperature rises, metabolism is promoted. In addition, when the body temperature rises, immune function is enhanced (“Modern people with low heat” published by Takahisa Hiraishi, published in the Nikkei morning edition of March 26, 2011). For this reason, the present inventors can further promote metabolism, enhance immune function, improve symptoms such as hypothermia, coldness, and increase intestinal temperature by increasing body temperature. I thought that I could improve symptoms such as constipation.
The present inventors have further studied based on these findings, and have completed the present invention.
That is, the present invention includes the following inventions.

(1) An oral body temperature increasing agent characterized by containing a Artemisia plant or a processed product thereof as an active ingredient.
(2) An oral metabolism promoter comprising an Artemisia plant or a processed product thereof as an active ingredient.
(3) An oral immune function enhancer comprising a Artemisia plant or a processed product thereof as an active ingredient.
(4) The agent according to any one of (1) to (3), wherein the Artemisia princeps Pampan. Is a Artemisia princeps Pampan.
(5) The agent according to any one of (1) to (4) above, wherein the processed product of Artemisia plant is a dried product of fresh leaves and / or stems of Artemisia.
(6) The agent according to any one of (1) to (5) above, wherein the processed product of Artemisia plant is a pulverized product of dried leaves and / or stems of Artemisia plant.
(7) The agent according to any one of (1) to (6), wherein the dosage form is a tablet, capsule, chewable agent, film agent, powder, pill, or granule.
The oral body temperature increasing agent according to (1), which is used for promoting metabolism.
The body temperature increasing agent for oral use according to (1), which is used for enhancing immune function.

(8) A method for raising the body temperature of a mammal, which comprises administering a Artemisia plant or a processed product thereof to the mammal.
(9) A method for promoting metabolism of a mammal, comprising administering a Artemisia plant or a processed product thereof to the mammal.
(10) A method for enhancing the immune function of a mammal, comprising administering a Artemisia plant or a processed product thereof to the mammal.

(11) An Artemisia plant or a treated product thereof as a body temperature increasing agent for oral use, or a composition containing the same.
(12) A Artemisia plant or a treated product thereof, or a composition containing the same, as an oral metabolism promoter.
(13) A Artemisia plant or a processed product thereof, or a composition containing the same, as an oral immune function enhancer.

(14) Use of a Artemisia plant or a processed product thereof for producing an oral body temperature increasing agent.
(15) Use of a Artemisia plant or a processed product thereof for producing an oral metabolism promoter.
(16) Use of a Artemisia plant or a processed product thereof for producing an oral immune function enhancer.

According to the present invention, the body temperature can be increased continuously. In particular, the oral temperature increasing agent of the present invention can effectively increase the body temperature of the trunk such as the abdomen. For this reason, if the body temperature increasing agent of this invention is used, a sufficient body warming feeling can be obtained. According to the present invention, the body can be warmed to effectively prevent or improve hypothermia, coldness, and the like. Moreover, according to this invention, a metabolism can be accelerated | stimulated by the body temperature raising effect | action. The immune function can be enhanced by the action of raising body temperature. For this reason, the body temperature increasing agent of this invention is useful also for healthy maintenance, promotion, etc. of a healthy person. Furthermore, the Artemisia plant, which is an active ingredient in the present invention, can be used continuously because it has few side effects and is highly safe.

FIG. 1 is a diagram showing changes in body surface temperature (skin temperature) of the abdomen due to intake of dried mugwort. FIG. 2 is a diagram showing changes in the surface temperature of the middle finger pad due to intake of dried mugwort. FIG. 3 is a diagram showing changes in the surface temperature of the back of the middle finger due to intake of dried mugwort. FIG. 4 is a diagram showing changes in body surface temperature and changes in blood flow in various parts of the body due to ingestion of mugwort-containing capsules or control capsules. FIG. 5 is a graph showing the change over time in the body surface temperature of the abdomen due to the intake of mugwort-containing capsules or control capsules. FIG. 6 is a graph showing changes in the body surface temperature of the ankle over time due to the intake of mugwort-containing capsules or control capsules. FIG. 7 is a graph showing changes in the eardrum temperature over time due to the intake of mugwort-containing capsules or control capsules. FIGS. 8A to 8C are diagrams showing changes in the sensation level with the intake of mugwort-containing capsules or control capsules over time (A in FIG. 8: sensation of the whole body, B: sensation of the hand, C in FIG. 8). Foot experience). FIG. 9 is a diagram showing changes in body surface temperature and changes in blood flow in various parts of the body due to intake of mugwort-containing capsules or control capsules. FIG. 10 is a diagram showing the change over time in the body surface temperature of the abdomen due to the intake of mugwort-containing capsules or control capsules. FIG. 11 is a diagram showing the change over time in the body surface temperature of the forehead due to the intake of mugwort-containing capsules or control capsules.

The oral body temperature increasing agent of the present invention (also referred to simply as a body temperature increasing agent in the present specification) contains a Artemisia plant or a processed product thereof as an active ingredient.
In the present invention, a Artemisia plant or a processed product thereof is used to increase body temperature. Since Artemisia plants or their processed products have a body temperature increasing action, the body can be warmed in a low temperature environment such as in winter. Further, by raising the body temperature, for example, hypothermia, coldness, etc. can be prevented or improved. Moreover, metabolism is accelerated | stimulated by a body temperature rising by this invention. Furthermore, since the immune function is activated when the body temperature rises, the Artemisia plant or a processed product thereof is also useful for enhancing the immune function. For this reason, the body temperature increasing agent of the present invention is preferably used for, for example, promoting metabolism and enhancing immune function.

In the present invention, the increase in body temperature means that the body temperature is increased when the mugwort plant or treated product thereof is orally ingested, compared with the case where the mugwort plant or treated product thereof, which is the active ingredient in the present invention, is not taken orally. It means that a warming sensation of the body can be obtained when a mugwort plant or a processed product thereof is orally ingested. When the body temperature increasing agent of the present invention is used, the body temperature rises, so that usually a sufficient body warming feeling can be obtained. The body temperature increasing agent of the present invention is particularly preferably used for increasing the temperature of the trunk such as the abdomen. The rise in body temperature is measured, for example, by measuring the temperature of the body surface (preferably, the body surface of the trunk such as the abdomen), the eardrum temperature, and the like.

The Artemisia plant is not particularly limited, and examples thereof include the following plants. These may use only 1 type and may use 2 or more types.
Artemisia princeps Pampan., Artemisia japonica Thunb., Artemisia capillaris Thunb., Artemisia montana (Nakai) Pamp., Artemisia maritima (Artemisia maritima) unalaskensis Rydberg, Artemisia fukudo Makino, Artemisia glomerata Ledeb., Artemisia trifurcata Steph. ex Spreng., Artemisia stolonifera (Maxim.) Komar. koidzumii Nakai), Artemisia iwayomogi Kitam., Artemisia gilvescens Miq., Artemisia momiyamae Kitam., Artemisia rubripes Nakai, Artemisia indica Haremi et al. .), Artemisia laciniata Wil ld.), Artemisia dubia Wall. ex DC., Artemisia kurramensis Quazilbash, Artemisia koidzumii var. tsuneoi, Artemisia feddei Leveil. et Vaniot, T. var. littoricola (Kitam.) Kitam.), Artemisia congesta Kitam., Asagiri (Artemisia schmidtiana Maxim.), Artemisia keiskeana Miq., Taragon (Artemisia dracunculus L.), Artemisia dracunculus L. var. pedunculosa (Koidz.) Kitam.), Artemisia insularis Kitam., Chinese carrot (Artemisia apiacea Hance), Carrot carrot (Artemisia annua L.), Artemisia arctica Less. subspulen sachalinen ), China (Artemisia cina Berg.), White-spotted Artemisia (Artemisia arctica Less. Subsp. Sachalinensis Hult) en f. villosa (Koidz.) Kitam.), Artemisia stelleriana Besser, Artemisia sinanensis Yabe, Artemisia selengensis Turcz., Artemisia argyi Lev. et Vant., Artemisia argyi Lev. et Vant. campestris L., Artemisia absinthium L., Artemisia sieversiana Willd., Artemisia vulgaris L., Artemisia monophylla Kitam., Artemisia monophylla Kitam., Artemisia igniaria Maxim. (Artemisia pedunculosa Miq.), Artemisia lactiflora Wall. Ex DC., Artemisia abrotanum, Artemisia abrosii, Artemisia anomala, Artemisia aylata, Artemisia aylata (Artemisia dubia var. Subdigitata), Inufukudo (Artemisia fauriei) , Artemisia freyniana, Artemisia freyniana f. Discolor, Artemisia glomerata var. Leontopodioides, Artemisia indica var. Maximowiczii, Artemisia indica var. Artemisia japonica var. Angustissima, Artemisia koidzumii var. Megaphylla, Artemisia lagocephala, Artemisia latifolia, Artemisia latifolia, Artemisia mongolica, Artemisia mongolica, Artemisia mongolica ), Artemisia opulenta, Artemisia palustris, Artemisia pubescens, Artemisia rubripes f. Luxurians, Artemisia scoparia, Kibanite Motegi (Artemisia sibirica), Hiro Hayama mugwort (Artemisia stolonifera), Makinohayomogi (Artemisia subulata), Moriyomogi (Artemisia sylvatica), Kobanoyomogi (Artemisia verbenacea), Pekin'yomogi (Artemisia viridisquama), Stewartia pyrrosia lingua mugwort (Artemisia viridissima).

As for the Artemisia plant in the present invention, those normally used for food are suitable, for example, Artemisia princeps Pampan., Artemisia montana (Nakai) Pamp., Artemisia capillaris Thunb. Artemisia indica Willd. And the like are preferred, and Artemisia princeps Pampan. Are more preferred. Mugwort (Artemisia princeps Pampan.) Is an annual perennial plant of Asteraceae that grows naturally in Yamano. It is a perennial period for species conservation in the spring growth period, the maturity period from spring to summer solstice, and the summer solstice to winter period. Plant.

The Artemisia plant in the present invention may be the whole plant body or a part of the plant body. Examples of the plant include leaves, leaf stems, stems, flowers, roots and the like. Preferred are leaves, leaf stems, stems, etc. More preferred are leaves and / or stems, and still more preferred are leaves.

The treated product of the Artemisia plant is not particularly limited as long as it is a Artemisia plant that has been subjected to some treatment. Examples of the treatment include drying, pulverization, crushing, chopping, heating (steaming, boiling, etc.) and the like, and these two or more treatments may be performed in combination. The treated product of Artemisia plant is preferably a dried product of Artemisia, more preferably a pulverized product or a crushed product of the dried product.

The dried product may be, for example, a product obtained by drying a raw Artemisia plant, or a product obtained by subjecting a Artemisia plant to a heat treatment with a boil or the like and then drying it. Preferably, a raw Artemisia plant is dried.

In a preferred embodiment of the present invention, dried leaves and / or stems of Artemisia are used. The dried leaves and / or stems of Artemisia plants are preferably dried raw leaves and / or stems. Moreover, it is preferable that the processed product of the Artemisia plant in this invention is the ground material of the dry leaf and / or stem of a Artemisia plant. The size of the pulverized product is not particularly limited.

In the production of a Artemisia plant treated product, for example, when a Artemisia plant is heat-treated by boiling or the like, it is usually preferable to heat at about 80 to 100 ° C. In general, the heat treatment time is preferably about 1 to 30 minutes. The drying method is not particularly limited, and drying may be performed under any conditions such as sun drying, natural drying, drying using a ventilation dryer, freeze drying (freeze drying drying), hot air drying, and the like. Drying without heating is preferable, and for example, sun drying, natural drying, medium / low temperature ventilation drying, and freeze drying are more preferable. The drying time may be appropriately set depending on the drying method. As a typical example, if it is sun-drying, it is usually about 12 to 72 hours, and if it is ventilation drying, it is usually about 12 to 72 hours. If so, it is usually about 3 to 12 hours.

♪ Artemisia plants can be collected from the wild and can be used. Also, Artemisia plants and their processed products are commercially available, and commercially available products can also be used. For example, frozen mugwort, dried mugwort and the like are commercially available from Ueno Tadashi Co., Ltd. (Osaka, Osaka, Japan).

The Artemisia plant in the present invention, when using various Artemisia plants stably throughout the year, is usually harvested from the Artemisia plant in the growing or mature period, frozen after pretreatment, or dried after pretreatment. Store in a laid-out form and use when necessary. When using a pulverized product of Artemisia plant, it is usually pulverized before storage or at the time of use.

The Artemisia plant used in the present invention can be pretreated as follows, for example. For example, it is harvested and harvested at a position about 25 cm above the upper part of the plant of the genus Artemisia, and is treated with a stem until the drying process is completed. Usually, it is washed with primary water to remove mud and insects attached to the Artemisia plant. After rinsing, the mugwort plant is moved to the secondary rinsing tank using a draining Conveyor. Secondary water washing usually uses two kinds of washing machines to clean mud, sand, foreign matters and so on. The product after the secondary washing is usually dehydrated with a centrifugal dehydrator. The dehydrated portion is dried after visual inspection of foreign matter, foreign grass, hay, etc.
Further, after completion of drying, it is preferable to separate and separate leaves, leaf stems and stems as necessary. For example, when using leaves, it is preferable to collect the leaves and leaf stem portions.

The body temperature increasing agent containing the Artemisia plant or its processed product of the present invention is orally ingested or orally administered.

The oral body temperature increasing agent of the present invention may be composed of an Artemisia plant which is an active ingredient or a processed product thereof, or may be a composition containing components other than the active ingredient as desired.
The body temperature increasing agent of the present invention may be used not only as a medicine but also as, for example, a health food, a functional food, or a food or drink. In the present invention, the Artemisia plant or its processed product is preferably used as an active ingredient of a composition for increasing body temperature, such as a food or drink, a health food, a functional food, or a pharmaceutical composition.

The body temperature increasing agent containing the Artemisia plant or its processed product as an active ingredient is preferably a solid preparation such as a tablet, capsule, chewable agent, film agent, powder, pill or granule. These preparations can be easily produced by using the Artemisia plant or its processed product as it is, or by mixing various pharmaceutically acceptable additives as desired, and using well-known well-known preparation methods. Is done. The additive is not particularly limited, and pharmaceutically acceptable known ones can be used. For example, excipients (for example, lactose, starch, crystalline cellulose, dextrin, glucomannan, etc.), binders (for example, Starch, gelatin, carmellose sodium, methylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, polyvinylpyrrolidone, etc.), disintegrant (eg, starch, carmellose sodium, etc.), lubricant (eg, talc, magnesium stearate, calcium stearate) Etc.), antioxidants (eg nitrite, ascorbic acid, cysteine etc.), colorants (eg tar pigments, licorice extract, etc.), preservatives (eg paraoxybenzoates, benzalkonium chloride, chlorobutanol) Etc.), Ko Ingu agents (e.g., hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, ethyl cellulose, cellulose acetate phthalate, etc.), a plasticizer (e.g., glycerin, etc.), and the like. Among these, it is preferable to include glucomannan and the like. Moreover, as long as the effect of this invention is produced, you may include the component etc. which have body temperature raising effects other than a Artemisia plant or its processed material.

The solid preparation may be an enteric preparation. For example, when a patient with hyperacidosis orally ingests a Artemisia plant or a processed product thereof, there may be a strong irritation to the stomach, but by using an enteric preparation, the present invention reduces the irritation to the stomach. The body temperature increasing effect of can be sufficiently obtained. Examples of the enteric agent include preparations obtained by applying an enteric coating to the solid preparation (for example, tablets, powders, pills and the like having an enteric coating), enteric capsules and the like. The method for producing the enteric preparation is not particularly limited, and the composition containing the Artemisia plant or a processed product thereof may be appropriately used by using a known enteric capsule or a method used for producing an enteric coating agent. That's fine. In addition, as the preparation of the present invention, a sustained-release preparation is also preferable. For example, by containing glucomannan or the like, the Artemisia plant or its processed product can be gradually released, so that irritation to the stomach or the like can be further reduced. .

The content of the Artemisia plant or its processed product in the preparation is usually about 0.000001 to 99% by mass in the final preparation. Preferably, it is a preparation containing about 10 to 300 mg per dose unit, more preferably about 50 to 200 mg per dose unit, more preferably about 100 to 200 mg per dose unit as a Artemisia plant or a processed product thereof.

In the case of food and drink, for example, it is produced by blending a body temperature increasing agent containing the above Artemisia plant or a processed product thereof at the time of producing the food or drink. Although it does not specifically limit as food-drinks, A solid food is suitable.

The intake or dosage of the body temperature increasing agent containing the Artemisia plant or its treated product is not particularly limited as long as the effect of the present invention is exhibited, but for example, as an Artemisia plant or its treated product as an active ingredient, About 10 to 300 mg per dose is preferably taken orally or administered. More preferably, about 50 to 200 mg per dose, more preferably about 100 to 200 mg per dose, is orally ingested or orally administered as an active ingredient Artemisia plant or processed product thereof. More preferably, it is about 10 to 300 mg per time, more preferably about 50 to 200 mg per time, particularly preferably about 100 to 200 mg per time as dry leaves and / or stems of Artemisia plants. Ingested or administered orally. In addition, it is preferable to take the above amount usually after meals about 1 to 3 times a day. When the above-mentioned amount of the Artemisia plant or its treated product is ingested, the body temperature increasing action usually continues from about 2 hours to 24 hours after ingestion. More preferably, the above-mentioned amount of Artemisia plant or its processed product is taken orally within about 2 hours after meal, more preferably within about 1 hour after meal, particularly preferably within about 30 minutes after meal.

The subject to ingest or administer the Artemisia plant or its processed product is not particularly limited, but mammals including humans, birds and the like are preferable, mammals including humans are more preferable, and humans are more preferable. For example, a human who needs a treatment for cold or hypothermia is particularly suitable. In addition, the present invention is not limited to humans who need treatment for improvement of cold or hypothermia, but is also useful for maintaining the health of, and promoting the health of healthy individuals.

The body temperature increasing agent containing the Artemisia plant or its processed product of the present invention can also be used for increasing body temperature, promoting metabolism or enhancing immune function of animals other than humans. For example, a composition containing a Artemisia plant or a processed product thereof can be used as animal feed or animal medicine. The animal may be any useful animal, and is not particularly limited. For example, dogs, cats, monkeys, rats, mice, cows, pigs, horses, hamsters, rabbits, squirrels, guinea pigs, ferrets, weasels, chinchillas, momonga, prairie dogs. Mammals such as; birds such as chickens. Of these, mammals are preferable, and dogs, cats, horses, and the like are more preferable.

Since the Artemisia plant or its processed product has an effect of raising body temperature when taken orally, it can improve the symptoms and diseases caused by cold or hypothermia. By orally administering the body temperature increasing agent of the present invention to mammals including humans, it is possible to effectively prevent or treat coldness, hypothermia and the like. For example, animals with hypothermia have low intestinal temperatures, and thus women with cold symptoms have a lot of constipation. According to the present invention, since the body temperature can be raised, the intestinal temperature can be raised, and constipation can be prevented or improved. Moreover, since metabolism is accelerated | stimulated by the body temperature raising effect | action, a basal metabolism can also be improved or improved. Furthermore, since the immune function becomes active when the body temperature rises, it can also be used for enhancing the immune function. The body temperature increasing agent of the present invention is also useful as a means for warming a cooled body in a cold region, a low-temperature environment such as winter.

Oral metabolism promoter containing mugwort plant or processed product thereof as active ingredient (in this specification, also simply referred to as metabolism promoter) and oral immune function containing mugwort plant or treated product thereof as active ingredient An enhancer (also referred to simply as an immune function enhancer in the present specification) is also encompassed in the present invention.
The Artemisia plant or its treated product in the metabolism promoter and immune function enhancer of the present invention, and preferred embodiments thereof are the same as the above-mentioned body temperature increasing agent. Preferred forms, usage methods, and the like of the metabolism promoter and immune function enhancer of the present invention are also the same as the above-mentioned body temperature raising agent.

The present invention also includes a method for increasing the body temperature of a mammal, in which a mugwort plant or a processed product thereof is orally administered to the mammal. In a preferred embodiment of the method of the present invention, a body temperature increasing agent containing the above-mentioned Artemisia plant or a processed product thereof as an active ingredient is orally administered to a mammal. The body temperature increasing agent and preferred embodiments thereof are as described above.

The present invention also includes a method of promoting metabolism of a mammal by orally administering a Artemisia plant or a processed product thereof to the mammal. In a preferred embodiment of the method of the present invention, a metabolism promoter containing the above-mentioned Artemisia plant or a processed product thereof as an active ingredient is orally administered to a mammal. The metabolism promoting agent and preferred embodiments thereof are as described above.

The present invention also includes a method for enhancing the immune function of a mammal by orally administering a Artemisia plant or a processed product thereof to the mammal. In a preferred embodiment of the method of the present invention, an immune function enhancer containing the above-mentioned Artemisia plant or a processed product thereof as an active ingredient is orally administered to a mammal. The immune function enhancer and preferred embodiments thereof are as described above.

The present invention also includes a Artemisia plant or a treated product thereof, or a composition containing the same, as an oral body temperature increasing agent. Oral body temperature raising agents are the same as those described above.
The present invention also includes a Artemisia plant, a processed product thereof, or a composition containing the same as an oral metabolism promoter. The oral metabolism promoter is the same as described above.
The present invention also includes a Artemisia plant, a processed product thereof, or a composition containing the same, as an oral immune function enhancer. The oral immune function enhancer is the same as described above.
Artemisia plants, processed products thereof, preferred embodiments thereof, administration methods thereof and the like are the same as those in the above-mentioned body temperature increasing agent.

The present invention also includes the use of a Artemisia plant or a treated product thereof for producing an oral body temperature increasing agent. Oral body temperature raising agents are the same as those described above.
The present invention also includes use of a Artemisia plant or a processed product thereof for producing an oral metabolism promoter. The oral metabolism promoter is the same as described above.
The present invention also includes use of a Artemisia plant or a processed product thereof for producing an oral immune function enhancer. The oral immune function enhancer is the same as described above.
Artemisia plants, processed products thereof, and preferred embodiments thereof are the same as those in the above-mentioned body temperature increasing agent.

Hereinafter, the present invention will be specifically described by way of examples, but the present invention is not limited to these examples.

Example 1
(Method for preparing dried mugwort)
The leaves of the collected mugwort (Artemisia princeps Pampan.) Were naturally dried and then finely pulverized to obtain a dried mugwort.

(Manufacture of tablets)
The above dried mugwort and gelatin were mixed by a conventional method and then tableted to obtain 1000 tablets containing 140 mg of dried mugwort in 1 tablet (200 mg).
This tablet was used for the following tests.

Example 2
The test was carried out in a prefabricated thermostatic chamber (size (inside): vertical 3.43 m, horizontal 3.03 m, height 2.16 m) (manufactured by Toyobo Engineering Co., Ltd.). During the test, the temperature in the prefabricated constant temperature room was kept at a temperature of 24 ± 0.5 ° C. and a humidity of 50%.
For skin temperature measurement, a temperature sensor (temperature sensor for BDT100, manufactured by Bio Research Center) is attached to the left wrist, left middle finger pad, left hand middle finger back, left ankle, left foot middle finger back, neck, right shoulder, back, and abdomen. Then, the skin temperature change of each part was measured. Blood flow was measured by attaching a sensor of a semiconductor laser blood flow device (ALF21D, manufactured by ADVANCE) to the left ring finger. Skin temperature and blood flow data of each part of the body were taken into a personal computer via Maclab (registered trademark) / 16S (manufactured by ADInstruments), and the skin temperature and blood flow of each part were measured once per second. Data recording and measurement condition setting were performed using the application program Chart V4.2 (manufactured by AD Instruments).
The eardrum temperature was measured using an ear thermometer (trade name: Ken-on, manufactured by OMRON Corporation). Heart rate variability analysis (used soft fractlet manufactured by Sumitomo Dainippon Pharma Co., Ltd.) was performed as an index of autonomic nervous tone.

(Test procedure)
Subject A: 21-year-old female with coldness Subject B: 22-year-old female without coldness Subjects A and B were fasted for 3 hours or longer (only specified water can be taken). Before entering the temperature-controlled room, subjects A and B change into test clothes (upper body is a trainer and a white coat. The lower half is a long zuhon covering the ankle of the jersey material) and fill out the questionnaire. did. As soon as this work was finished, I entered a temperature-controlled room.
After entering the room, temperature sensors were attached to the left wrist, left hand middle finger pad, left hand middle finger back, left ankle, left foot middle finger back, neck, right shoulder, back and abdomen. A sensor was attached to the left ring finger for blood flow measurement. An electrode was attached to the chest for electrocardiogram measurement.

After completion of device installation, electrocardiogram recording (autonomous recording) and body surface temperature (skin temperature) measurement were started. During the test period, subjects A and B were resting while sitting on a chair with their feet down. After about 30 minutes, both were fed the test formulation.

About 30 minutes after the start of measurement, subjects A and B were allowed to take 1 tablet of test preparation within 2 minutes together with 50 mL of purified water adjusted to 37 ° C. so as not to affect body temperature. Two minutes after the start of ingestion of the test preparation was defined as 0 minutes after ingestion (0 minutes after ingestion) and 0 minutes in the time series of the experiment including before ingestion. The skin temperature and blood flow were averaged 3 minutes before to 1 minute before intake (-5 to -3 minutes in time series) as the average before intake. Skin temperature recording and electrocardiogram recording were completed 1 hour and 12 minutes after ingestion (time series 72 minutes). During the test, they showed a soundless DVD to prevent the subject from getting sleepy.

Results Regarding changes in the skin temperature at each site, both subjects A and B who ingested the test preparation produced in Example 1 had a skin temperature at each site of the body in an environment at room temperature of 24 ° C. after ingestion of the test formulation. Rose. The increase in the skin temperature of each part of the body described below is an increase temperature with respect to the average temperature before intake of each part.
For example, regarding the left wrist skin temperature, in subject A, the left wrist skin temperature increased after ingestion of the test preparation, and the wrist skin temperature increased 2.4 ° C. at 72 minutes after ingestion. In subject B, the skin temperature of the left wrist increased for about 0.6 ° C. during the test period.

Regarding the skin temperature of the middle finger pad of the left hand, in subject A, the skin temperature increased by about 8 ° C. 30 minutes after ingestion of the test preparation, and increased by 5.6 ° C. compared to before ingestion at 72 minutes after ingestion. In subject B, the skin temperature of the middle finger pad of the left hand rose about 2 ° C. at 30 minutes after ingestion.

Regarding the skin temperature of the middle finger back on the left hand, in subject A, the skin temperature increased after ingestion of the test preparation, and the wrist skin temperature increased 4.2 ° C. at 72 minutes after ingestion. In subject B, the skin temperature of the middle finger back on the left hand rose about 1 ° C. at 30 minutes after ingestion.

Regarding the skin temperature of the abdomen, in subject A, the skin temperature gradually increased after ingestion of the test preparation, and the skin temperature increased by about 1 ° C. at 72 minutes after ingestion. In subject B, the skin temperature of the abdomen increased by about 0.4 ° C. compared to the average before ingestion at 72 minutes after ingestion.

In both subjects A and B, the skin temperature of the left ankle gradually decreased. The skin temperature on the back of the middle toe, neck, shoulders and back of the left foot remained almost unchanged during the study period for both subjects.

Fig. 1 to 3 show the skin temperature (body surface temperature) measurement results of the abdomen, left hand middle finger pad, and left hand middle finger back. 1 to 3, the solid line is the subject A (cool woman), and the wavy line is the subject B (non-cool woman).

Regarding blood flow, subjects A and B increased blood flow after taking the test preparation. The analysis result of the heart rate variability showed no change in subjects A and B during the test period.

The average change in skin temperature of each part of the body from intake of the test preparation to the end of measurement was calculated by the following formula.
(Average change in skin temperature) = (Total temperature value in the time period / Number of temperature data)-(Average temperature before ingestion)
In addition, 2 to 24 minutes after ingestion of water (and tablets) was taken as the first period, 25 to 47 minutes as the middle period, and 48 to 71 minutes as the latter period, and the average changes in skin temperature and blood flow in each period were determined. In calculating the average change, the average before intake was used as a reference.

Table 1 shows the average amount of change in skin temperature by region (° C.) and the average amount of change in blood flow (no unit) during the test period (72 minutes after ingestion). Table 2 shows the results in the first, middle and later stages of the test. The average amount of change in skin temperature (° C.) and the average amount of change in blood flow (no unit) are shown.

Thus, when the test preparation produced in Example 1 was ingested, both subjects A and B increased body temperature, thereby increasing the temperature of the terminal finger, but a significant increase in body temperature particularly in subject A (cool woman). Was observed. If you are resting as in this experiment with the clothes described under an environment lower than body temperature (room temperature 24 ° C.), the body temperature and body surface temperature of the normal extirpation part, for example, wrist, fingertip, ankle, toetip, etc. will be moderate descend. It is a surprising finding that the body surface temperature (especially the abdominal skin temperature) increased under the environment of room temperature 24 ° C. only by ingestion of the test preparation, and in particular, a marked increase in body temperature was observed in the subject A with cold. there were.

Example 3
1. Experimental environment and equipment The equipment used in the test of Example 3 (first test and second test) is as follows.
<Constant temperature room>
・ Prefabricated constant temperature chamber (same as used in Example 1) Toyobo Engineering Co., Ltd. ・ Dehumidification Purifier DW-S101 (trade name, manufactured by Sharp Corporation)
・ Heat-vaporizing humidifier HV-T50CX (trade name, manufactured by Sharp Corporation)

<Measurement equipment>
Skin temperature (body surface temperature) measurement and portable temperature recorder (Product name COMPACT THERMOLOGGER AM8000K, Anritsu Keiki Co., Ltd.)
・ Microprobe thermometer 6ch THERMOMETER (Product name, Bioresearch Corporation)

Measurement of blood flow was performed using a semiconductor laser blood flow device (product name: Laser Doppler ALF21 / 21D, ADVANCE Co., Ltd.).

Electrode for measuring heart rate variability and electrocardiogram (Vitrode M-150 (Nihon Kohden Kansai Co., Ltd.)
・ Electrocardiograph (Product name AMPLIFIER CASE, Sanei Medical Support Co., Ltd.)
・ Analysis software (Product name Fraclet 3.0Jr., Dainippon Pharmaceutical Co., Ltd.)
Heart rate measurement
BIOVIEW 1000A NEC (product name, Tochigi NEC Corporation) was used.

Measurement of eardrum temperature, eardrum temperature OMRON ear thermometer KENON-kun MC-510 (trade name, OMRON Healthcare Co., Ltd.)

<Set temperature>
The laboratory temperature settings and the like in the first and second tests are as follows. The front room (standby room) is not a constant temperature room.

The reference temperature of 22 ° C. in the first test is a temperature at which the body surface temperature of the peripheral part of the body gradually decreases under the temperature condition at the time when the test was performed, and it feels “cold” to a person who is cold. . In the second test, the reason why the set temperature in the laboratory (constant temperature chamber and front room) was changed from 22 ° C to 25 ° C was that the outside air temperature increased due to summer, and the body surface temperature of the peripheral part of the body decreased. This is because the temperature at which the user feels “cold” is different from that in the first test.

2. Measurement method The test was performed twice for each subject, and a crossover test was performed. Measurements were made at least 3 days between each test for each subject. On the day of the test, after entering the front room, the subject changed into test clothes (the upper body was a short-sleeved T-shirt and a white robe, and the lower body was long pants covering up to the ankle of the jersey material). In order to understand the sleep time of the previous day, I answered a questionnaire. Next, the subject entered the laboratory (constant temperature chamber), and sensors (temperature sensor for measuring body surface temperature and sensor for measuring blood flow) were attached to each part of the body (Table 4 below). . After the sensor was attached, measurement of body surface temperature (skin temperature), blood flow and heart rate variability was started. After being habituated to the environment for a certain period of time, the subjects were given the mugwort-containing capsules or control capsules described below. Thereafter, the body surface temperature, blood flow, and heart rate variability were observed. Changes in body sensation and eardrum temperature were also observed periodically.
During the test, subjects were kept resting in a sitting position and prohibited as much conversation, movement, and sleep as possible. In particular, the left hand was instructed not to move as much as possible in order to wear a blood flow meter. During the measurement, DVD images without sound were watched to prevent sleepiness. At the end of the study, the questionnaire was answered to learn about changes in subjects during the study.

Table 4 shows the sensor or electrode mounting sites in the first and second tests.

The eardrum temperature was measured and recorded by the subject himself with an OMRON ear thermometer Ken-on MC-510 (trade name, OMRON Healthcare Co., Ltd.) at intervals of about 10 to 15 minutes.
For the eardrum temperature, an average value measured twice in the first test was used. In the second test, the ear thermometer measures the highest eardrum temperature in the ear, so the highest value is considered appropriate as the measurement value, and it is measured three times each time. The maximum of 3 times was taken as the measured value of the eardrum temperature at that time. When the difference between the three measurement values was 0.3 ° C. or more, the measurement was performed again.

In the evaluation of the sensation, immediately after measuring the eardrum temperature, the sensation level is entered in the subject using the visual analog scale (5-level evaluation from 1 (cold) to 5 (warm)) for the whole body, hand, and foot. I let you.

3. Test period First test: May to July Second test: July to August Both the first test and the second test were conducted in a laboratory in Hikone city, Shiga, Japan.
In consideration of changes in body temperature during the menstrual cycle of women, the test period was set to 2 weeks from the 6th day counting from the start date of menstruation when the body temperature was stable. The same subject started the test from the same time as possible.

4). Intake (sample)
Unboiled, raw mugwort (Artemisia princeps Pampan.) Leaves were air dried (72 hours at 30 ° C.). 1000 g of this dried mugwort leaf was pulverized by a jet mill (trade name: Conjet System α-mkIV, manufactured by Seishin Enterprise Co., Ltd.) (Crushing conditions: pressure 0.6 to 0.7 MPa, speed 100 g / hr). Of the obtained dried powder of mugwort, 100 mg is filled into capsules (trade name Cellulose White Capsule No. 2 manufactured by Matsuya Co., Ltd.), and only dried mugwort leaves are filled. Capsules (100 mugwort-containing capsules) containing 100 mg of dry leaf powder were produced. As a control, a capsule (control capsule) containing 100 mg of wheat flour colored green instead of the dried powder of mugwort leaves was prepared.
In the test, the subject was orally ingested with two capsules (intake: 200 mg) of a mugwort-containing capsule and a control capsule as a sample together with designated water (37 ° C., 100 mL). At this time, the subjects did not know the contents.

5. About the subjects Healthy female college students aged 18 to 23 or Tadashi Ueno employees (20 women) were used as subjects.
The subjects were categorized as cold or non-cooled by conducting the following 1-8 coldness judgment questionnaires.
1. I think it's more “chilly” than other people.
2. It is hard to have cold on the waist, limbs, or part of the body.
3. Since it gets cold in winter, I always use electric blankets and warmers.
4). The whole body may get cold and hard.
5. I wear thick socks even in summer because my feet get cold.
6). The place where air conditioning works is cold and hard.
7). I think it ’s much more thick than many other people.
8). I think my limbs are colder than many people.

The subjects were asked to answer the question in the questionnaire with ◎ (subject to considerable symptoms), ○ (sometimes (somewhat), × (not applicable at all)).
For questions on the important items 1 to 3 above, ◎ → 3 points, ○ → 2 points, × → 0 points For questions on the above 4-8 items, ◎ → 2 points, ○ → 1 points, × → 0 The total score of 7 points or more was set as a cooling property group, and the other points were set as a non-cooling property group.

The above questionnaire and the standard of cold syndrome are based on the “Chilling Diagnosis Criteria” in the biopharmaceutical magazine Vol 41, 2, 85-96, 1987, “Recognition and treatment of“ cold cold ”in Chinese medicine” It is a thing. In Terasawa's paper, only ○ × is answered, and 2 important items and 1 reference item are calculated, and 4 or more points are cool. However, when recruiting subjects by this method, since mild coldness is also included as subjects, we made a judgment by improving the questionnaire a little.

6). Precautions for the subjects The subjects were asked to pay attention to the following contents from the day before the test, and in order to check whether they met the necessary conditions immediately before the test, as well as the presence of stress, mood before and after the test, and physical condition, Went.
(1) Precautions on the previous day ・ Avoid strong foods such as ginger and chili.
・ Refrain from excessive eating, drinking and eating.
(2) Notes on the day ・ You can drink water, but you cannot drink coffee, tea or juice.
・ Wake up at least one hour before the start of the test. Align the wake-up time on the day of the test.
・ Move the way from the home to the laboratory on the day of the test.
・ People who usually travel by bicycle from their home to the laboratory on a rainy day decided to travel by bus for two days.
-On the day of the test, wear trousers and socks and move from your home to the laboratory. Stockings and tights are not allowed.

7). Number of test subjects 11 people in the 1st test, 11 people in the non-cool property group in the 2nd test

8). First meal restriction test: Fasted for 3 hours or more (starting with specified water only) before the start of the test.
Second test: Fasted for 2 hours or more before the start of the test, and specified water and sandwich were ingested 1 hour before sample ingestion.

9. Judgment method of effect Since body temperature fluctuates somewhat depending on the basal body temperature of each individual and the environmental conditions such as the day's weather, analysis was performed with the amount of change based on the value at the time of ingesting the mugwort-containing capsule or the control capsule. The following two statistical methods were used for the analysis.
(1) Paired t test (Software used: Microsoft Excel)
(2) Repeated measurement two-way analysis of variance (Software used: prism)
The criteria for determining the effect are shown in Table 5 below. In this case, since the subject of the experiment was a human, up to 10% level was judged as a significant difference.

10. Test and results <First test and results>
Artemisia leaf dry matter intake: 200mg
Room temperature: 22 ° C
Measurement items: body surface temperature (forehead, neck, wrist, fingertip (left middle finger belly), abdomen, ankle, toe tip (left middle finger back)), eardrum temperature, bodily sensation, autonomic nerve, and blood flow Diet: None (subject Was fasted 3 hours before taking the sample (mugwort-containing capsule or control capsule).)
Subjects: 11 people with coldness according to the above criteria (excludes subject data that could not be measured due to mechanical failure, etc., so 11 data for wrist, fingertip, abdomen, blood flow and autonomic nerves, 10 for neck and ankle data (The forehead, toe, and eardrum temperature data are the results of 9 people, and the bodily sensation data are the results of 11 people.)

<Measurement method>
After the subject entered the front room, they changed their clothes and answered the questionnaire. Thereafter, the subject entered the temperature-controlled room, and the sensor was attached to each part of the body. Measurement of body surface temperature, blood flow and heart rate variability was started 20 minutes before ingestion of the sample (mugwort-containing capsule or control capsule). After habituation to the environment for 20 minutes, samples were ingested with 100 mL of 37 ° C. water within 2 minutes. The course of body surface temperature, blood flow, and heart rate variability was observed for 60 minutes after sample ingestion. Changes in body sensation and eardrum temperature were also observed periodically.

<Result>
FIG. 4 shows changes in body surface temperature of each part of the body due to ingestion of mugwort-containing capsules or control capsules. The temperature change on the vertical axis in FIG. 4 is the average value of the change in body surface temperature from 2 to 60 minutes after ingestion, with the average value for 3 minutes before ingestion as the reference value. In FIG. 4, the white bar is the control capsule intake group, and the black (gray) bar is the mugwort-containing capsule intake group. In FIG. 4, “blood flow” is unitless.
FIG. 5 shows changes over time in the body surface temperature of the abdomen due to the intake of mugwort-containing capsules or control capsules. FIG. 6 shows changes in ankle over time due to intake of mugwort-containing capsules or control capsules. FIG. 7 shows the temporal change of the eardrum temperature with the intake of mugwort-containing capsules or control capsules.
8A to 8C show changes over time in the sensation level due to the intake of mugwort-containing capsules or control capsules. 8A is a whole body sensation, FIG. 8B is a hand sensation, and FIG. 8C is a foot sensation.
In FIGS. 5 to 8, white circles (◯) are control capsule intake groups, and black circles (●) are mugwort-containing capsule intake groups. Also, the results shown in FIGS. 5 to 8 are average values of the measurement data.

From these results, as for the body surface temperature, the temperature of the abdominal body surface significantly increased compared to the control group in the time course change and the average after ingestion after ingestion of the mugwort-containing capsule (FIGS. 4 and 5). . Moreover, in the time-dependent change in the body surface temperature of the ankle, the temperature drop was significantly suppressed at the 1% level as compared with the control group after ingesting the mugwort-containing capsule (FIG. 6).
The eardrum temperature showed a tendency to maintain body temperature as compared with the control group (control capsule intake group) due to the intake of mugwort-containing capsules (FIG. 7).
In the evaluation of the bodily sensation, in the foot and whole body, the results of the decrease in the bodily sensation level were obtained in the mugwort-containing capsule intake group as compared with the control group (A to C in FIG. 8). The level of bodily sensation was significantly higher in the group receiving the mugwort-containing capsules at the 10% level in the foot than in the two-way analysis of variance and at the 1% level in the whole body.

In the first test, a decrease in body sensation (whole body and foot) level was suppressed by mugwort ingestion, and a decrease in body temperature was suppressed in the abdomen, ankle, and eardrum temperature. This indicates that mugwort intake has a higher effect of raising the body surface temperature of the trunk than at the periphery. The fact that it affects the heat production of the trunk, it was thought that the built-in work such as peristaltic movement was activated by ingestion of mugwort. The first test was aimed at verifying the effect of improving coldness by ingesting mugwort, so all subjects were cold. If mugwort affects the temperature rise of the trunk, it is possible that heat production is more active in non-cold than in cold, so the second test should be performed with non-cold subjects It was.

<Second test and results>
Artemisia leaf dry matter intake: 200mg
Room temperature: 25 ° C
Measurement items: Body surface temperature (forehead, neck, wrist, fingertip (left middle finger belly), abdomen, back, ankle, toe tip (left middle finger back)), eardrum temperature, body sensation, autonomic nerve and blood flow Subjects were infused with the specified sandwich and water one hour prior to ingesting the sample (mugwort-containing capsule or control capsule).
Subjects: 11 people with non-coldness according to the above criteria (excludes subject data that could not be measured due to mechanical problems, etc., so forehead, neck, wrist, abdomen, back, ankle, toe, eardrum temperature, autonomic nerve, and blood flow data Is the result of 11 people, and the data of the fingertips is the result of 10. The data of bodily sensation is the result of 11 people.)

<Changes from the first test>
Since attention is paid to the rise in body surface temperature rather than the effect of suppressing the cooling, the temperature of the laboratory (constant temperature chamber) was set to 25 ° C. instead of 22 ° C. which gradually feels cooling.
From the first test, it was found that mugwort particularly affects the body surface temperature of the trunk. For this reason, the subject was changed from the coolness to the non-coolness that is considered to be active in the heat production of the trunk.
Since mugwort was thought to be related to the heat production of the trunk, that is, the peristaltic movement of the internal organs, the changes after meals that the peristaltic movement would be more active were examined.
The back where brown adipocytes related to heat production are present is added to the measurement site.
In this questionnaire, items related to beverage intake, exercise, and clothing were added, and the conditions were further aligned.

<Measurement method>
Subjects ingested a meal (designated sandwich and water) one hour prior to ingestion of the sample (mugwort-containing capsule or control capsule). After the meal, subjects entered the front room, changed clothes and answered the questionnaire in the front room. Enter the temperature-controlled room (25 ° C) about 30 minutes before taking the sample (mugwort-containing capsule or control capsule), attach the sensor to each part of the body, and from 20 minutes before taking the mugwort-containing capsule (or control capsule) Measurements of body surface temperature, blood flow, and heart rate variability were started. After habituation to the environment for 20 minutes, samples (mugwort-containing capsules or control capsules) were ingested with 100 mL of 37 ° C. water within 2 minutes. The course of body surface temperature, blood flow, and heart rate variability was observed for 60 minutes after sample ingestion. Changes in body sensation and eardrum temperature were also observed periodically.

<Result>
FIG. 9 shows changes in body surface temperature of each part of the body due to the intake of mugwort-containing capsules or control capsules. The temperature change on the vertical axis in FIG. 9 is the average value of the change in body surface temperature from 2 to 60 minutes after ingestion, with the average value for 3 minutes before ingestion as the reference value. In FIG. 9, the white bar is the control capsule intake group, and the black (gray) bar is the mugwort-containing capsule intake group. In FIG. 9, “blood flow” is unitless.
FIG. 10 shows changes over time in the body surface temperature of the abdomen due to the intake of mugwort-containing capsules or control capsules. FIG. 11 shows the change over time in the body surface temperature of the forehead due to the intake of mugwort-containing capsules or control capsules. 10 to 11, white circles (◯) are control capsule intake groups, and black circles (●) are mugwort-containing capsule intake groups. Moreover, the result shown by FIG.10 and FIG.11 is an average value of measurement data.

Based on the above results, the body surface temperature for the forehead of the average temperature change by period after ingestion (from 2 minutes to 20 minutes after ingestion is the first period, from 21 minutes to 40 minutes after ingestion is in the middle period, from 41 minutes from ingestion to It was significantly higher at a level of 1% compared to the control group after ingestion of mugwort-containing capsules (FIG. 9). Furthermore, the temporal changes in the forehead and abdominal body surface temperature were significantly higher after ingestion of mugwort-containing capsules as compared with the intake of control capsules (FIGS. 10 and 11).
In the second test, a test was conducted on non-chilling subjects, but the environmental temperature was different, but in the second test as well as in the first test, ingestion of mugwort-containing capsules in the abdomen compared to the control group The body surface temperature also increased significantly. From this, it has been found that mugwort is particularly effective for heat production in the trunk.

Summary of Example 3 From the results of the first test and the second test, it was found that the temperature rises particularly in the abdomen due to the intake of mugwort. Therefore, it has been found that mugwort ingestion has the effect of raising the temperature of the central part of the body (trunk), such as the abdomen, by generating heat regardless of the constitution, such as coldness or non-coldness.
In the second test, the body temperature did not increase due to the intake of mugwort as in the first test in the abdomen, but this was thought to be due to the difficulty of confirming the change due to the effect of food intake before mugwort intake.

Formulation Example 1
Gelatin capsules (manufactured by Sansho Pharmaceutical Co., Ltd.) are filled with 100 mg of the dried mugwort produced in Example 1, and then the capsules are enteric-coated with corn-derived protein (zein) to produce an enteric preparation. did.
In the same manner as in the above formulation example, a capsule containing, for example, 10 mg to 300 mg of dried mugwort leaves in one capsule can be prepared.

Claims

An oral body temperature increasing agent characterized by containing an Artemisia plant or a processed product thereof as an active ingredient.
An oral metabolism promoter characterized by containing an Artemisia plant or a processed product thereof as an active ingredient.
An oral immune function enhancer characterized by containing an Artemisia plant or a processed product thereof as an active ingredient.
The agent according to any one of claims 1 to 3, wherein the Artemisia princeps Pampan.
The agent according to any one of claims 1 to 4, wherein the processed product of the Artemisia plant is a dried product of fresh leaves and / or stems of the Artemisia plant.
The agent according to any one of claims 1 to 5, wherein the processed product of Artemisia plant is a pulverized product of dried leaves and / or stems of Artemisia plant.
The agent according to any one of claims 1 to 6, wherein the dosage form is a tablet, capsule, chewable agent, film agent, powder, pill, or granule.
A method for increasing the body temperature of a mammal, characterized by orally administering a Artemisia plant or a processed product thereof to the mammal.
A method for promoting metabolism of mammals, comprising orally administering a Artemisia plant or a processed product thereof to the mammal.
A method for enhancing the immune function of a mammal, comprising orally administering a Artemisia plant or a processed product thereof to the mammal.
As a body temperature increasing agent for oral use, a Artemisia plant or a processed product thereof, or a composition containing the same.
As an oral metabolism promoter, Artemisia plants or processed products thereof, or compositions containing the same.
As an oral immune function enhancer, a Artemisia plant or a processed product thereof, or a composition containing the same.
¡Use of Artemisia plants or their processed products to produce an oral body temperature increasing agent.